赛隆药业集团股份有限公司 关于董事、高级管理人员 2025年薪酬的确认及2026年薪酬方案

Core Viewpoint - The company has proposed a compensation plan for its directors and senior management for 2026, which aims to enhance their motivation and creativity while aligning their performance with the company's operational effectiveness [1][2]. Group 1: 2025 Compensation Confirmation - The compensation details for the company's directors and senior management for 2025 were reviewed and confirmed, with specific individuals noted as non-independent directors who do not receive compensation [1]. Group 2: 2026 Compensation Plan - The 2026 compensation plan applies to both directors (including independent directors) and senior management [2]. - The plan will take effect upon approval by the shareholders' meeting and will automatically become invalid once a new plan is approved [3]. - Independent directors will receive an annual allowance of 180,000 yuan, paid monthly [4]. - Non-independent directors, including the chairman and vice-chairman, will have a salary structure consisting of a base salary and performance-based compensation, with performance pay accounting for at least 50% of the total compensation [5]. - Senior management's compensation will also consist of a base salary and performance pay, with similar performance-based criteria [6]. Group 3: Additional Provisions - Compensation for directors and senior management who leave due to changes in position or resignation will be calculated based on their actual tenure [7]. - All compensation figures are pre-tax, with the company responsible for withholding taxes and social insurance as per regulations [7]. - The company reserves the right to reduce or stop performance pay if directors or senior management violate obligations that result in losses to the company [7]. - The human resources and finance departments are authorized to implement the compensation plan, while the compensation and assessment committee will oversee its execution [7].

SaiLong-赛隆药业集团股份有限公司 关于董事、高级管理人员 2025年薪酬的确认及2026年薪酬方案 - Reportify